Smita Asare

机构：Quantum Leap Healthcare Collaborative, The University of Texas Southwestern Medical Center · ORCID：0000-0001-6707-0917

发表论文 86 篇 · 总被引 3452 次 · h-index 21

代表论文

• Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy (2023 · Cancer Cell · 被引 190)
• Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery (2023 · Clinical Cancer Research · 被引 20)
• Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial (2023 · Cell Reports Medicine · 被引 18)
• Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer (2023 · JAMA Network Open · 被引 14)
• Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer (2024 · Cell Reports Medicine · 被引 10)
• Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes (2023 · Frontiers in Oncology · 被引 6)